Authum Investment & Infrastructure Ltd to acquire stake in Rivaara Labs Pvt Ltd

Today, Authum Investment & Infrastructure Limited has entered into the following binding agreements:

(a) Share Subscription cum Purchase Agreement dated August 25, 2025 ("SSPA") with Rivaara Labs Private Limited ("Rivaara Labs") and Mr. Siddharth Bharat Daftary, recording the terms and conditions for:

(i) Rivaara Labs issuing and offering and the Company subscribing to 3,60,00,000 (Three Crore and Sixty Lakhs) cumulative compulsorily convertible participating preference shares of Rivaara Labs ("CCPS"); and

(ii) the Company purchasing from certain existing shareholders of Rivaara Labs, and certain existing shareholders of Rivaara Labs selling to the Company:

- 1,58,42,000 (One Crore Fifty-Eight Lakh Forty-Two Thousand) equity shares of Rivaara Labs, and

- 4,09,88,011 (Four Crore Nine Lakh Eighty-Eight Thousand and Eleven) CCPS, in aggregate, constituting 35.09% (Thirty Five point Zero Nine Per Cent) of the total voting rights of Rivaara Labs; and

The consummation of the transactions contemplated the SSPA is subject to satisfactory fulfilment of certain conditions precedent recorded in the SSPA, including receipt of the necessary corporate authorizations. Upon consummation of the transactions contemplated under the SSPA, the Company shall be entitled to exercise 35.09% (Thirty-Five point Zero Nine Per Cent) of the total voting rights of Rivaara Labs.

Rivaara Labs is engaged in the business of:

- establishing and operating diagnostic service centres including pathology, imaging, PCR testing and genomic sequencing

- Distribution, marketing, manufacturing point of care diagnostic kits and equipment based on molecular biology in India;

- RT-PCR (Reverse Transcription Polymerase Chain Reaction) related diagnostic services, such as development, manufacture, distribution, and sale of test kits, reagents, enzymes, and related consumables used for the detection, quantification, or monitoring of infectious diseases in humans, as well as the provision of clinical laboratory testing, sample collection, and diagnostic reporting services associated with such RT-PCR tests; and

- Rendering of digital healthcare products and / or services related to diagnostics.

This acquisition aligns with our long-term strategy of diversifying our portfolio while investing in sectors that demonstrate both stability and growth potential. Our intention is to nurture and expand this business, maximizing value creation for all stakeholders and ensuring a sustainable, profitable future for the Company.

Source : Equity Bulls

Keywords

AuthumInvestmentandInfrastructure BindingAgreement StakeAcquisition RivaaraLabs